Bone Marrow & Stem Cell Transplant

The FDA has accepted and granted priority review to tab-cel, a treatment for Epstein Barr virus-positive posttransplant lymphoproliferative disease.

The application of remestemcel-L, a potential first-of-its-kind treatment for pediatric patients following stem cell transplants, has been resubmitted for FDA approval after addressing previous concerns.

Alexandra Gomez Arteaga, MD, discussed findings from a retrospective study comparing Orca-T with posttransplant cyclophosphamide graft-vs-host disease prophylaxis to assess outcomes in patients undergoing hematopoietic cell transplant.

The phase 2 PONALFIL trial evaluating a ponatinib regimen shows promise for long-term survival in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Neel Bhatt, MD, discussed the importance of long-term patient monitoring following hematopoietic cell transplantation.

The phase 3 SIERRA study revealed that only Iomab-B recipients achieved the primary end point of durable complete remission.

Chakra Chaulagain, MD, discusses findings from a comprehensive examination of National Cancer Database data from 2004 to 2020 regarding the utilization of autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

In a feature article incorporating Case-Based Roundtable® discussions, we look at the evolution of management for chronic graft-vs-host disease (cGVHD) following allogeneic hematopoietic cell transplantation and the impact of effective non-steroid therapies for cGVHD.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the specific patient subgroups for whom autologous transplant remains the best course of action for.

In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.

Warren Fingrut, MD, discussed a study looking at HLA antibody burden among patients with blood cancers, particularly women who have carried multiple pregnancies.

Saad Z. Usmani, MD, MBA, FACP, FASCO, delves into the development of new treatments for patients with multiple myeloma.

Betty Hamilton, MD, discussed findings from a quality of life study in patients with FLT3 ITD-positive acute myeloid leukemia who underwent allogeneic stem cell transplant.

Chelsea Peterson, DO, discussed a real-world study investigating ruxolitinib in patients with steroid-refractory graft-vs-host disease.

Michael Scordo, MD, discussed findings from a phase 2 study investigating new antithymocyte globulin dosing models for ex vivo CD34-selected allogeneic stem cell transplants.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.

Jeff Auletta, MD, discusses findings from a study evaluationg posttransplant cyclophosphamide in unmatched stem cell transplants.

In an interview with Targeted Oncology, Chakra Chaulagain, MD, discussed the trends of higher rates of autologous hematopoietic stem cell transplantation refusal among patients with multiple myeloma.

Kayla Giannetti, MSN, APRN-CNP, discusses a study presented at the 2024 Transplantation and Cellular Therapy Tandem Meetings investigating the link between patient frailty and stem cell transplants.

Alice Bertaina, MD, discussed combining T-allo10 gene therapy with stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.

Valentina Ardila, MD, discusses findings from a study investigating the role of obesity in patients undergoing stem cell transplants.

Alice Bertaina, MD, discusses combining of T-allo10, a donor-derived cell product, with haploidentical stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.

Daniel Cancilla, MD, discusses a study performed at the Cleveland Clinic where a new protocol for plerixafor usage for stem cell transplantation was implemented with the goal of cost savings.

Peterson discusses the investigation of ruxolitinib in the second line for patients with acute graft-vs-host disease following allogeneic hematopoietic stem cell transplant.

The latest developments across the fields of stem cell transplantation and cellular therapy were presented at the 2024 Tandem Meetings in San Antonio, Texas, from February 21-24, 2024.

Orca-T demonstrated survival rates vs post-transplant cyclophosphamide in patients with hematologic malignancies receiving myeloablative conditioning, according to findings from a retrospective analysis.

Betty K. Hamilton, MD, discusses findings from a study comparing gilteritinib vs placebo post-allogeneic hematopoietic cell transplantation for the treatment of patients with FLT3-ITD-positive acute myeloid leukemia.

Michael Scordo, MD, discusses the implications of a new approach to dosing antithymocyte globulin in patients undergoing an allogeneic hematopoietic stem cell transplant.

Stem cell treatments offer hope for a variety of conditions. However, access to these potentially life-altering procedures is often hampered by social factors such as socioeconomic status, race, cultural background, and geographic location.

Adding prophylactic acyclovir therapy to the treatment regimen for patients undergoing a stem cell transplant reduced the rates of chemotherapy-induced oral mucositis, a common and significant adverse effect of the treatment.